Francisco Casas-Maldonado
Overview
Explore the profile of Francisco Casas-Maldonado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alvarez-Gutierrez F, Casas-Maldonado F, Soto-Campos G
Arch Bronconeumol
. 2024 Oct;
PMID: 39428316
No abstract available.
2.
Dominguez-Ortega J, Munoz-Gall X, Delgado-Romero J, Casas-Maldonado F, Blanco-Aparicio M
Open Respir Arch
. 2024 Jun;
6(3):100331.
PMID: 38883425
No abstract available.
3.
Alvarez-Gutierrez F, Casas-Maldonado F, Soto-Campos G, Blanco-Aparicio M, Delgado J, Galo A, et al.
Arch Bronconeumol
. 2024 May;
60(8):503-509.
PMID: 38697903
The concept of "remission" in asthma has been around for a long time and it has been a controversial topic. Despite the attempts of some studies to characterize this entity,...
4.
Casas-Maldonado F, Alvarez-Gutierrez F, Blanco Aparicio M, Ribas C, Cisneros Serrano C, Soto Campos G, et al.
Open Respir Arch
. 2023 Oct;
5(3):100252.
PMID: 37810425
Introduction And Objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or...
5.
Padilla-Galo A, Moya Carmona I, Ausin P, Carazo Fernandez L, Garcia-Moguel I, Velasco-Garrido J, et al.
Respir Res
. 2023 Sep;
24(1):235.
PMID: 37770889
Background: The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain....
6.
Torres-Duran M, Lopez-Campos J, Calle Rubio M, Montero-Martinez C, Priegue Carrera A, Amaro Rodriguez R, et al.
Int J Chron Obstruct Pulmon Dis
. 2023 Aug;
18:1691-1700.
PMID: 37559832
Purpose: Administration of exogenous alpha-1 antitrypsin (AAT) is the only specific therapy for the management of pulmonary morbidity in patients with AAT deficiency. It requires weekly or biweekly intravenous infusions,...
7.
Alvarez-Gutierrez F, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, Gonzalez-Barcala F, Carretero-Gracia J, et al.
Open Respir Arch
. 2023 Jul;
4(3):100192.
PMID: 37496585
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs....
8.
Miravitlles M, Turner A, Torres-Duran M, Tanash H, Rodriguez-Garcia C, Lopez-Campos J, et al.
Eur Respir J
. 2023 Mar;
61(3).
PMID: 36997232
No abstract available.
9.
Miravitlles M, Turner A, Torres-Duran M, Tanash H, Rodriguez-Garcia C, Lopez-Campos J, et al.
Respir Res
. 2023 Feb;
24(1):57.
PMID: 36800958
No abstract available.
10.
Miravitlles M, Turner A, Torres-Duran M, Tanash H, Rodriguez-Garcia C, Lopez-Campos J, et al.
Respir Res
. 2022 Dec;
23(1):352.
PMID: 36527073
Background: Alpha-1 antitrypsin deficiency (AATD) is a rare disease that is associated with an increased risk of pulmonary emphysema. The European AATD Research Collaboration (EARCO) international registry was founded with...